228 related articles for article (PubMed ID: 18975354)
1. Effects of disease-modifying antirheumatic drug treatment on the expression of RANKL and osteoprotegerin in synovial tissue: comment on the article by Haynes et al.
Catrina AI; Klareskog L
Arthritis Rheum; 2008 Nov; 59(11):1685; author reply 1685-6. PubMed ID: 18975354
[No Abstract] [Full Text] [Related]
2. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
3. Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome.
Haynes D; Crotti T; Weedon H; Slavotinek J; Au V; Coleman M; Roberts-Thomson PJ; Ahern M; Smith MD
Arthritis Rheum; 2008 Jul; 59(7):911-20. PubMed ID: 18576301
[TBL] [Abstract][Full Text] [Related]
4. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
[TBL] [Abstract][Full Text] [Related]
5. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.
Tunyogi-Csapo M; Kis-Toth K; Radacs M; Farkas B; Jacobs JJ; Finnegan A; Mikecz K; Glant TT
Arthritis Rheum; 2008 Aug; 58(8):2397-408. PubMed ID: 18668542
[TBL] [Abstract][Full Text] [Related]
6. Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium.
Bramlage CP; Kaps C; Ungethüm U; Bramlage P; Koziolek M; Wessels J; Krenn V; Pruss A; Müller GA; Strutz F; Burmester GR; Häupl T
Scand J Rheumatol; 2008; 37(6):401-9. PubMed ID: 18830904
[TBL] [Abstract][Full Text] [Related]
7. Characterization of synovial cell clones isolated from rheumatoid arthritis patients: possible involvement of TNF-alpha in reduction of osteoprotegerin in synovium.
Zhao B; Takami M; Miyamoto Y; Suzawa T; Yamada A; Mochizuki A; Yasuhara R; Wang X; Inoue T; Namiki O; Sakamoto K; Kamijo R
Cytokine; 2008 Jan; 41(1):61-70. PubMed ID: 18083042
[TBL] [Abstract][Full Text] [Related]
8. Real-time quantitative PCR to detect changes in synovial gene expression in rheumatoid arthritis after corticosteroid treatment.
Gerlag DM; Boyle DL; Rosengren S; Nash T; Tak PP; Firestein GS
Ann Rheum Dis; 2007 Apr; 66(4):545-7. PubMed ID: 16984938
[TBL] [Abstract][Full Text] [Related]
9. What is the rank of RANKL in spondylarthritis?
Loddenkemper K; Burmester GR
Arthritis Rheum; 2008 Mar; 58(3):641-4. PubMed ID: 18311809
[No Abstract] [Full Text] [Related]
10. Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade.
Rooney T; Edwards CK; Gogarty M; Greenan L; Veale DJ; FitzGerald O; Dayer JM; Bresnihan B
Rheumatol Int; 2010 Nov; 30(12):1571-80. PubMed ID: 19847430
[TBL] [Abstract][Full Text] [Related]
11. Lymphoid aggregation is not lymphoid neogenesis: comment on the article by Klaasen et al.
Cañete JD; Pablos JL
Arthritis Rheum; 2010 Sep; 62(9):2825-6. PubMed ID: 20496427
[No Abstract] [Full Text] [Related]
12. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
Gerlag DM; Tak PP
Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
[TBL] [Abstract][Full Text] [Related]
13. Inclusion of glucocorticoids in recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: Comment on the article by Saag et al.
van Tuyl LH; Lems WF; Voskuyl AE; Dijkmans BA; Boers M; Kerstens PJ
Arthritis Rheum; 2009 Jan; 61(1):141-2; author reply 141-2. PubMed ID: 19116962
[No Abstract] [Full Text] [Related]
14. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade: comment on the article by Buch et al.
Schiff MH
Arthritis Rheum; 2005 Jan; 52(1):364-5; author reply 365. PubMed ID: 15641081
[No Abstract] [Full Text] [Related]
15. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis.
Boumans MJ; Thurlings RM; Yeo L; Scheel-Toellner D; Vos K; Gerlag DM; Tak PP
Ann Rheum Dis; 2012 Jan; 71(1):108-13. PubMed ID: 22072013
[TBL] [Abstract][Full Text] [Related]
16. Synovial synoviolin in relation to response to TNF blockade in patients with rheumatoid arthritis and psoriatic arthritis.
Klaasen R; Wijbrandts CA; van Kuijk AW; Pots D; Gerlag DM; Tak PP
Ann Rheum Dis; 2012 Jul; 71(7):1260-1. PubMed ID: 22345123
[No Abstract] [Full Text] [Related]
17. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.
Saxne T; Larsson L; Geborek P
Arthritis Rheum; 2004 Sep; 50(9):3049-50; author reply 3050-1. PubMed ID: 15457477
[No Abstract] [Full Text] [Related]
18. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
[No Abstract] [Full Text] [Related]
19. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis.
Feldmann M; Brennan FM; Williams RO; Woody JN; Maini RN
Best Pract Res Clin Rheumatol; 2004 Feb; 18(1):59-80. PubMed ID: 15123038
[TBL] [Abstract][Full Text] [Related]
20. An alternative, autonomic rationale for decreased risk of myocardial infarction in patients with rheumatoid arthritis responsive to anti-tumor necrosis factor therapy: comment on the article by Dixon et al.
Holman AJ
Arthritis Rheum; 2008 Jun; 58(6):1886; author reply 1886. PubMed ID: 18512805
[No Abstract] [Full Text] [Related]
[Next] [New Search]
